Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis

Molecular Cancer

Volumn 11, Issue , 2012, Pages

  Bozkaya, Giray ^a   Korhan, Peyda ^a   Çokakli, Murat ^a   Erdal, Esra ^a   Saǧol, Özgül ^a   Karademir, Sedat ^a   Korch, Christopher ^b   Atabey, Neşe ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Differentiation; Hepatocellular carcinoma (HCC); Hepatocyte Growth Factor (HGF) c Met; Invasion; Mucin 1 (MUC1)

Indexed keywords

BETA CATENIN; MUCIN 1; MYC PROTEIN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA;

ARTICLE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

BETA CATENIN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEPATOCYTE GROWTH FACTOR; HUMANS; INDOLES; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS; MUCIN-1; PHOSPHORYLATION; PIPERAZINES; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MET; PROTO-ONCOGENE PROTEINS C-MYC; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 84865969027     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-11-64     Document Type: Article

References (49)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576. 10.1053/j.gastro.2007.04.061, 17570226.
2. Malenstein HV, Pelt JV, Verslype C. Molecular classification of hepatocellular carcinoma. Eur J Cancer 2011, 47:1789-1797. 10.1016/j.ejca.2011.04.027, 21612914.
3. Wong CM, Ng IO. Molecular pathogenesis of hepatocellular carcinoma. Liver Int 2008, 28:160-174.
4. Whittaker S, Marais R, Zhu AX. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010, 29:4989-5005. 10.1038/onc.2010.236, 20639898.
5. Liu Y, He J, Li C, Benitez R, Fu S, Marrero J, Lubman DM. Identification and confirmation of biomarkers using an integrated platform for quantitative analysis of glycoproteins and their glycosylations. J Proteome Res 2010, 9:798-805. 10.1021/pr900715p, 2838716, 19961239.
6. Zender L, Kubicka S. Molecular pathogenesis and targeted therapy of hepatocellular carcinoma. Onkologie 2008, 31:550-555.
7. Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signalling pathway in cancer. Eur J Cancer 2010, 46:1260-1270. 10.1016/j.ejca.2010.02.028, 3412517, 20303741.
8. Stoker M, Gherardi E, Perryman M, Gray J. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility. Nature 1987, 327:239-242. 10.1038/327239a0, 2952888.
9. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K, Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. Nature 1989, 342:440-443. 10.1038/342440a0, 2531289.
10. Miyazawa K, Tsubouchi H, Naka D, Takahashi K, Okigaki M, Arakaki N, Nakayama H, Hirono S, Sakiyama O, Takahashi K, Golida E, Daikuhara Y, Kitamura N. Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. Biochem Biophys Res Commun 1989, 163:967-973. 10.1016/0006-291X(89)92316-4, 2528952.
11. Nakamura T, Sakai K, Nakamura T, Matsumoto K. Hepatocyte growth factor twenty years on: much more than a growth factor. J Gastroenterol Hepatol 2011,
12. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Van de Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991, 251:802-804. 10.1126/science.1846706, 1846706.
13. Mohammed FF, Khokha R. Thinking outside the cell: proteases regulate hepatocyte division. Trends Cell Biol 2005, 15:555-563. 10.1016/j.tcb.2005.08.009, 16150595.
14. Schmidt C, Bladt F, Goedecke S, Brinkmann V, Zschiesche W, Sharpe M, Gherardi E, Birchmeier C. Scatter factor/hepatocyte growth factor is essential for liver development. Nature 1995, 373:699-702. 10.1038/373699a0, 7854452.
15. You H, Ding W, Dang H, Jiang Y, Rountree CB. C-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma. Hepatology 2011,
16. Borowiak M, Garratt AN, Wüstefeld T, Strehle M, Trautwein C, Birchmeier C. Met provides essential signals for liver regeneration. Proc Natl Acad Sci 2004, 101:10608-10613. 10.1073/pnas.0403412101, 490025, 15249655.
17. Van Andel Institute[Internet]. Bostwick Hepatocyte growth factor/scatter factor, Met and cancer references. 2010, http://www.vai.org/met/, Van Andel Institute[Internet]. Bostwick.
18. Marx-Stoelting P, Borowiak M, Knorpp T, Birchmeier C, Buchmann A, Schwarz M. Hepatocarcinogenesis in mice with a conditional knockout of the hepatocyte growth factor receptor c-Met. Int J Cancer 2009, 124:1767-1772. 10.1002/ijc.24167, 19123478.
19. Ueki T, Fujimoto J, Suzuki T, Yamamoto H, Okamoto E. Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology 1997, 25:619-623. 10.1002/hep.510250321, 9049208.
20. Kaposi-Novak P, Lee JS, Gòmez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 2006, 116:1582-1595. 10.1172/JCI27236, 1462944, 16710476.
21. Lai AZ, Abella JV, Park M. Crosstalk in Met receptor oncogenesis. Trends Cell Biol 2009, 19:542-551. 10.1016/j.tcb.2009.07.002, 19758803.
22. Singh PK, Behrens ME, Eggers JP, Cerny RL, Bailey JM, Shanmugam K, Gendler SJ, Bennett EP, Hollingsworth MA. Phosphorylation of MUC1 by Met modulates interaction with p53 and MMP1 expression. J Biol Chem 2008, 283:26985-26995. 10.1074/jbc.M805036200, 2556014, 18625714.
23. Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 2001, 6:339-353. 10.1023/A:1011379725811, 11547902.
24. Bafna S, Kaur S, Batra SK. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene 2010, 29:2893-2904. 10.1038/onc.2010.87, 2879972, 20348949.
25. Yuan SF, Li KZ, Wang L, Dou KF, Yan Z, Han W, Zhang YQ. Expression of MUC1 and its significance in hepatocellular and cholangiocarcinoma tissue. World J Gastroenterol 2005, 11:4661-4666.
26. Cao Y, Karsten U, Otto G, Bannasch P. Expression of MUC1, Thomsen-Friedenreich antigen, Tn, sialosyl-Tn, and alpha-2,6-linked sialic acid in hepatocellular carcinomas and preneoplastic hepatocellular lesions. Virchows Arch 1999, 434:503-509. 10.1007/s004280050375, 10394884.
27. Ichikawa T, Yamamoto T, Uenishi T, Tanaka H, Takemura S, Ogawa M, Tanaka S, Suehiro S, Hirohashi K, Kubo S. Clinicopathological implications of immunohistochemically demonstrated mucin core protein expression in hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 2006, 13:245-251. 10.1007/s00534-005-1070-4, 16708303.
28. Hattrup CL, Gendler SJ. MUC1 alters oncogenic events and transcription in human breast cancer cells. Breast Cancer Res 2006, 8:R37. 10.1186/bcr1515, 1779460, 16846534.
29. Singh PK, Hollingsworth MA. Cell surface-associated mucins in signal transduction. Trends Cell Biol 2006, 16:467-476. 10.1016/j.tcb.2006.07.006, 16904320.
30. Yuzugullu H, Benhaj K, Ozturk N, Senturk S, Celik E, Toylu A, Tasdemir N, Yilmaz M, Erdal E, Akcali KC, Atabey N, Ozturk M. Canonical Wnt signaling is antagonized by noncanonical Wnt5a in hepatocellular carcinoma cells. Mol Cancer 2009, 8:90. 10.1186/1476-4598-8-90, 2770486, 19849855.
31. Cokakli M, Erdal E, Nart D, Yilmaz F, Sagol O, Kilic M, Karademir S, Atabey N. Differential expression of caveolin-1 in hepatocellular carcinoma: correlation with differentiation state, motility and invasion. BMC Cancer 2009, 9:65. 10.1186/1471-2407-9-65, 2656543, 19239691.
32. Ishak KG, Anthony PP. Histological typing of tumors of the liver. WHO international histological classification of tumors 1994, Berlin: Springer Verlag, Sobin LH.
33. Poland PA, Kinlough CL, Rokaw MD, Blander JM, Finn OJ, Hughey RP. Differential glycosylation of MUC1 in tumors and transfected epithelial and lymphoblastoid cell lines. Glycoconj J 1997, 14:89-96. 10.1023/A:1018569100438, 9076518.
34. Monga SP, Mars WM, Pediaditakis P, Bell A, Mule K, Bowen WC, Wang X, Zarnegar R, Michalopoulos GK. Hepatocyte growth factor induces Wnt-independent nuclear translocation of β-catenin after Met-β-catenin dissociation in hepatocytes. Cancer Res 2007, 62:2064-2071.
35. Pan FY, Zhang SZ, Xu N, Meng FL, Zhang HX, Xue B, Han X, Li CJ. β-catenin signaling involves HGF-enhanced HepG2 scattering through activating MMP-7 transcription. Histochem Cell Biol 2010, 134:285-295. 10.1007/s00418-010-0729-3, 20677010.
36. Lillehoj EP, Lu W, Kiser T, Goldblum SE, Kim KC. MUC1 inhibits cell proliferation by a β-Catenin-dependent mechanism. Biochim Biophys Acta 2007, 1773:1028-1038. 10.1016/j.bbamcr.2007.04.009, 2349984, 17524503.
37. He XC, Yin T, Grindley JC, Tian Q, Sato T, Tao WA, Dirisina R, Westpfahl KSP, Hembree M, Johnson T, Wiedemann LM, Barrett TA, Hood L, Wu H, Li L. PTEN-deficient intestinal stem cells initiate intestinal polyposis. Nat Genet 2007, 39:189-198. 10.1038/ng1928, 17237784.
38. Herrera MB, Bruno S, Buttiglieri S, Tetta C, Gatti S, Deregibus MC, Bussolati B, Camussi G. Isolation and characterization of a stem cell population from adult human liver. Stem Cells 2006, 24:2840-2850. 10.1634/stemcells.2006-0114, 16945998.
39. Hernyk MH, Tsan R, Radinsky R, Gallick GE. Activation of c-Met in colorectal carcinoma cells leads to constitutive association of tyrosine-phosphorylated β-catenin. Clin Exp Metastasis 2003, 20:291-300. 10.1023/A:1024024218529, 12856716.
40. Sattler M, Pride YB, Ma P, Gramlich JL, Chu SC, Quinnan LA, Shirazian S, Liang C, Podar K, Chrisrensen JG, Salgia R. A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. Cancer Res 2003, 63:5462-5469.
41. Fan S, Wang JA, Yuan RQ, Rockwell S, Andres J, Zlatapolskiy A, Goldberg ID, Rosen EM. Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents. Oncogene 1998, 17:131-141. 10.1038/sj.onc.1201943, 9674697.
42. Ren J, Agata N, Chen D, Li Y, Yu W-H, Huang L, Raina D, Chen W, Kharbanda S, Kufe D. Human MUC1 carcinoma-associated protein confers resistance to genotoxic anti-cancer agents. Cancer Cell 2004, 5:163-175. 10.1016/S1535-6108(04)00020-0, 14998492.
43. Bressac B, Galvin KM, Liang TJ, Isselbacher KJ, Wands JR, Ozturk M. Abnormal syructure and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci 1990, 87:1973-1977. 10.1073/pnas.87.5.1973, 53607, 2155427.
44. Farazi PA, Glickman J, Horner J, Depinho RA. Cooperative interactions of p53 mutations, telomere dysfunction, and chronic liver damage in hepatocellular carcinoma progression. Cancer Res 2006, 66:4766-4773. 10.1158/0008-5472.CAN-05-4608, 16651430.
45. Chen GG, Merchant JL, Lai PB, Ho RL, Hu X, Okada M, Huang SF, Chui AK, Law DJ, Li YG, Lau WY, Li AK. Mutation of p53 in recurrent hepatocellular carcinoma and its association with the expression of ZBP-89. Am J Pathol 2003, 162:1823-1829. 10.1016/S0002-9440(10)64317-9, 1868140, 12759240.
46. Zeng G, Apte U, Micsenyi A, Bell A, Monga SP. Tyrosine residues 654 and 670 in beta-catenin are crucial in regulation of Met-beta-catenin interactions. Exp Cell Res 2006, 312:3620-3630. 10.1016/j.yexcr.2006.08.003, 1820835, 16952352.
47. Zhang W, Mendoza MC, Pei X, Ilter D, Mahoney SJ, Zhang Y, Ma D, Blenis J, Wang Y. Down-regulation of CMTM8 induces EMT-like changes via c-met/Erk signaling. JBC 2012,
48. Soussi T. Handbook of p53 mutation in cell lines. 2010, http://p53.free.fr/.
49. Lee HC, Kim M, Wands JR. Wnt/Frizzled signaling in hepatocellular carcinoma. Front Biosci 2006, 11:1901-1915. 10.2741/1933, 16368566.